arrow
Back
M

Marc‐Oliver Grimm

Friedrich Schiller University of Jena

53H-index
514Paper Count
1.8WCitation Count
Published Papers 158
Publication Date
Papillary renal cell carcinoma – exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review
err2026-05-27
err0
errOAAI
errMarit Ahrens; John Haanen; Laurence Albiges; Marine Gross Goupil; Ekaterini Boleti; Gwenaelle Gravis; Aude Fléchon; Marc Oliver Grimm; Jens Bedke; Philippe Barthélémy; Daniel Castellano; Begona Mellado; Philipp Ivanyi; Sylvie Rottey; Anne Flörcken; Cristina Suárez; Jose P. Maroto; Viktor Grünwald; Sjoukje Oosting; Jindrich Kopecky
errShare
errSave
Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group
err2026-05-19
err0
errOAAI
errIsabella C. Wiest; Lena Dreikhausen; Ralph Keller; Marcos Marin-Galiano; Laurence Albiges; Johannes Meran; Katharina Leucht; Stefan Rieken; Emilio Esteban; Friedemann Zengerling; Joseph Tintelnot; Marc-Oliver Grimm; Farastuk Bozorgmehr; Petros Christopoulos; Alexander Stein; Mascha Binder; Nicolai Härtel; Konrad Klinghammer; Viktor Grünwald; Michael Pogorzelski; Matthias P. Ebert
errShare
errSave
Prostate Artery Embolization vs. Holmium Laser Enucleation of the Prostate: A Matched Pair Analysis of Functional Outcomes and Complications
err2026-03-04
err0
errOAAI
errSimon Hannes Friedrich Leschik; Robert Große Siemer; Friedrich-Carl von Rundstedt; Philipp Gild; Christian P. Meyer; Raisa S. Abrams-Pompe; Ulf Teichgraeber; Thomas Lehmann; Susan Foller; Marc-Oliver Grimm; Tobias Franiel
errShare
errSave
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial☆
err2026-03-03
err0
errOAAI
errT.K. Choueiri; L. Albigès; D.F. McDermott; H.J. Hammers; B. Escudier; M. Burotto; E.R. Plimack; C. Porta; S. George; T. Powles; F. Donskov; M.B. Atkins; H. Gurney; C.K. Kollmannsberger; M.-O. Grimm; C. Barrios; D. Castellano; V. Grünwald; Y. Tomita; B.I. Rini
errShare
errSave
Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS
err2025-12-26
err0
errOAAI
errSaar, Matthias; Fizazi, Karim; Shore, Neal D.; Smith, Matthew; Damber, Jan-erik; Semenov, Andrey; Ribal, Maria J.; Birtle, Alison; Rigaud, Jerome; Wallis, Christopher J. D.; Grimm, Marc-oliver; Halabi, Susan; Armstrong, Andrew J.; Mohamed, Ateesha F.; Adorjan, Patrick; Srinivasan, Shankar; Verholen, Frank; Morgans, Alicia K.; Siemens, D. Robert
errShare
errSave
Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy
err2025-11-15
err0
errOAAI
errMarc-Oliver Grimm; Emma Karim; Venediktos Kapetanakis; Mickael Lothgren; Alessia Ogareva; Pragya Shukla; James Truscott; Camillo Porta
errShare
errSave
Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure
err2025-11-06
err0
errOAAI
errI.P. da Silva; L. Zimmer; J.-Y. Blay; M. Maio; J. Larkin; M.-O. Grimm; S. Puri; M.O. Butler; S. Patel; P.K. Thakkar; G.V. Long; I. Melero
errShare
errSave
First-line treatment of metastatic urothelial carcinoma
err2025-11-01
err0
PREAI
errZschabitz, Stefanie; Leucht, Katharina; Grimm, Marc-Oliver; Retz, Margitta
errShare
errSave
Artificial Intelligence-Assisted Biparametric MRI for Detecting Prostate Cancer—A Comparative Multireader Multicase Accuracy Study
err2025-08-29
err0
errOAAI
errDaniel Nißler; Sabrina Reimers-Kipping; Maja Ingwersen; Frank Berger; Felix Niekrenz; Bernhard Theis; Fabian Hielscher; Philipp Franken; Nikolaus Gaßler; Marc-Oliver Grimm; Ulf Teichgräber; Tobias Franiel
errShare
errSave
Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients—exploratory results from TITAN-RCC
err2025-08-28
err0
PREAI
errA. Fritzsch; K. Leucht; N. Röber; K. Conrad; R. Rothe; R. Wehner; U. Schumacher; E. Esteban; P. Barthélémy; M. Schmidinger; M. Schmitz; M.-O. Grimm
errShare
errSave
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial
err2025-08-07
err0
PREAI
errMatthew D. Galsky; Dean F. Bajorin; Yoshihiko Tomita; Dingwei Ye; Mads Agerbaek; Deborah Enting; Avivit Peer; Matthew Milowsky; Ko Kobayashi; Marc-Oliver Grimm; Frank Stenner; Justin M. David; Jun Li; Scott D. Chasalow; Federico Nasroulah; Abraham Apfel; Keziban Ünsal-Kaçmaz; Andrea Necchi
errShare
errSave
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial
err2025-06-20
err0
errOAAI
errMarc-Oliver Grimm; Matthew Smith; Maha Hussain; Fred Saad; Karim Fizazi; Natasha Littleton; Noman Paracha; Shankar Srinivasan; Frank Verholen; Bertrand Tombal
errShare
errSave
Belzutifan in Europe: A New Targeted Therapy for Clear Cell Renal Cancer
err2025-05-16
err0
PREAI
errCatherine Graham; Laurence Albiges; Marc-Oliver Grimm; Thomas Powles
errShare
errSave
IS THERE A ROLE OF THE ENDOGENOUS NEUROPEPTIDE OXYTOCIN IN THE PATHOPHYSIOLOGY OF ERECTILE DYSFUNCTION (ED)?
err2025-05-09
err0
PREAI
errAnastasiyeuskaya, Y.; Ueckert, S.; Becker, A. J.; Bannowsky, A.; Kuczyk, M-A; Grimm, M-O
errShare
errSave
Optimal length and temporal resolution of dynamic contrast-enhanced MR imaging for the differentiation between prostate cancer and normal peripheral zone tissue (vol 18, e0287651, 2023)
err2025-04-22
err0
errOAAI
errHellstern, Marius; Martinez, Carlos; Wallenhorst, Christopher; Beyersdorff, Dirk; Luedemann, Lutz; Grimm, Marc-Oliver; Teichgraeber, Ulf; Franiel, Tobias
errShare
errSave
Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa
err2025-04-16
err0
errOAAI
errM.-O. Grimm; J. Bedke; J. Nyarangi-Dix; W. Khoder; S. Foller; H.-J. Sommerfeld; M. Giessing; M. Heck; W. Meißner; A. Slee; K. Leucht; F. von Rundstedt; G. Theil; S. Buse; S. Siemer; P. Albers; C. Gratzke; M. Hohenfellner; A. Stenzl
errShare
errSave
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
err2025-04-01
err0
errOAAI
errL. Bergmann; L. Albiges; M. Ahrens; M. Gross-Goupil; E. Boleti; G. Gravis; A. Fléchon; M.-O. Grimm; J. Bedke; P. Barthélémy; D. Castellano; B. Mellado; P. Ivanyi; S. Rottey; A. Flörcken; C. Suarez; P. Maroto; V. Grünwald; S.F. Oosting; J. Kopecky; S. Zschäbitz; M. Boegemann; T. Buchler; G. Niegisch; P.J. Goebell; T. Waddell; F. Joly; F. Priou; M. Retz; S. Siemer; U. Zimmermann; D. Deckbar; I. Burkholder; A. Hartmann; J.B. Haanen
errShare
errSave
Nivolumab plus ipilimumab versus sunitinib for fi rst-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
err2024-11-01
err0
errOAAI
errTannir, N. M.; Albiges, L.; Mcdermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Barthelemy, P.; Plimack, E. R.; Portat, C.; George, S.; Donskov, F.; Atkins, M. B.; Gurney, H.; Kollmannsberger, C. K.; Grimm, M. -o.; Barrios, C.; Tomita, Y.; Castellano, D.; Gruenwald, V.; Rini, B. I.; Jiang, R.; Desilva, H.; Fedorov, V.; Lee, C. -w.; Motzer, R. J.
errShare
errSave